Cosmo Pharmaceuticals

Cosmo Pharmaceuticals S.p.A., a specialty pharmaceutical company, manufactures generic products and specialty drugs for gastro-intestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for inflammatory bowel diseases, such as ulcerative colitis and Crohn's Disease, and colon infections. Its products include Zacol NMX, a nutraceutical product for the treatment of colon disorders; and Lialda/Mezavant for the treatment of patients suffering from mild to moderate ulcerative colitis. The company's clinical development products include Budesonide MMX, a Phase III clinical trial product for induction of remission in patients with mild to moderate ulcerative colitis; Rifamycin SV MMX, a Phase III clinical trial product for travellers' diarrhoea; LMW Heparin MMX, a polysaccharidic drug that is applied as an injectable anticoagulant and anti-blood-clotting agent after a major surgery, which has completed Phase II clinical trials; and CB-03-01, chemical entity under Phase II clinical trial for the treatment of acne, alopecia, and hirsutism. Its preclinical projects comprise CB-01-16 for the prevention of opioid-induced constipation; CB-01-12, which is an Anti-TNFa; CB-01-13 for the prevention of colon cancer; CB-01-14, an antibiotic; and CB-01-09, an immunosuppressant. The company also engages in the manufacture of products for third parties. Cosmo Pharmaceuticals is headquartered in Lainate, Italy.

show less